FLNA:BMV
Filana Therapeutics Inc
MX$15.92
0.00%
(0.00) 1D
වප් 5, 12.05.31 ග්රිමවේ-6 · MXN
search
සියලු සංකේත
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_autoFLNA සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
වෙ.පො ප්රාග්ධනය
මි35.59
දළ පරිමාව
0.00
හඬ පරිමාණය
0.00
සති-52 ඉහළ
MX$56.00
සති-52 පහළ
MX$15.92
සේවකයින් ගණන
19
වෙ.පො ප්රාග්ධනය
මි35.59
දළ පරිමාව
0.00
හඬ පරිමාණය
0.00
සති-52 ඉහළ
MX$56.00
සති-52 පහළ
MX$15.92
සේවකයින් ගණන
19
පුවත් සහ කථා
වෙබ් මූලාශ්ර සහ ප්රවෘත්ති හවුල්කරුවන්ගෙන්
https://www.dars.gov.et/
·
සති 2කට පෙර
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss of $0.22 Per Share Beats Estimates, Shares Rise 8.92% - Fiscal Year Earnings
පැතිකඩ
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
Filana Therapeutics Inc ගැන